

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JINTIAN PHARMACEUTICAL GROUP LIMITED**  
**金天醫藥集團股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2211)**

**POSITIVE PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO (Cap.571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and the potential investors that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2014, the Group is expected to record an increase of not less than 30% in its consolidated net profit attributable to owners of the Company for the year ended 31 December 2014 as compared with that for the year ended 31 December 2013. The substantial increase is mainly attributable to the significant growth in both the retail and distribution businesses of the Group.

The Group is still in the process of finalizing its audited consolidated financial results for the year ended 31 December 2014. As such, this positive profit alert announcement is made solely on the basis of assessment by the Board with reference to its unaudited consolidated management accounts for the year ended 31 December 2014 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board and review by the external auditors of the Company.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Jintian Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and the potential investors that, based on a preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2014, the Group is expected to record an increase of not less than 30% in its consolidated net profit attributable to owners of the Company for the year ended 31 December 2014 as compared with that for the year ended 31 December 2013 (audited consolidated net profit attributable to owners of the Company for the year ended 31 December 2013 amounted to approximately RMB355,103,000). The substantial increase is mainly attributable to the significant growth in both the retail and distribution businesses.

In addition, the Group has acquired 157 pharmaceutical stores in the People’s Republic of China during 2014.

The Group is still in the process of finalizing its audited consolidated financial results for the year ended 31 December 2014. As such, this positive profit alert announcement is made solely on the basis of assessment by the Board with reference to the its unaudited consolidated management accounts for the year ended 31 December 2014 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board and review by the external auditors of the Company. Details of the financial performance of the Group will be contained in the annual results announcement of the Group for the year ended 31 December 2014, which is expected to be published in March 2015.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Jintian Pharmaceutical Group Limited**  
**Jin Dongtao**  
*Chairman*

Hong Kong, 12 February 2015

*As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Chu Chuanfu and Mr. Yang Jiacheng and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Chen Xiao.*